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Abstract
Well-differentiated thyroid carcinoma (WDTC) generally has a favorable prognosis.
However, patients with distant metastatic disease experience progression of disease with
a higher mortality. A subset of patients not previously described may challenge the
conventional dogma regarding the progressive nature of all metastatic WDTC. Through
analysis of our database, we identiﬁed patientswith distant metastatic WDTCand persistent,
minimally progressive disease. In all patients, persistent metastatic disease was conﬁrmed via
tissue biopsy, abnormal PETscan, and/or biochemical elevations in thyroglobulin or antibody
levels. Progression of disease was monitored clinically and with repeat imaging. We describe
ﬁve patients with WDTC and pulmonary metastases, aged 8–43 years at diagnosis.
All patients underwent initial surgery and radioactive iodine (RAI) ablation, with some
receiving multiple treatments. Persistent pulmonary metastatic disease was conﬁrmed over
decades (mean 22 years, range 8–42 years) with minimal progression despite no further
treatment beyond thyroid hormone suppression. Persistent disease was biopsy-proven in all
patients at a mean of 9.6 years from last RAI treatment. All patients had elevated
thyroglobulin or anti-thyroglobulin antibody levels,while three demonstrated metabolically
active disease with positive FDG uptake on PET scan, and one patient with persistent
radioactive iodine avid pulmonary metastasis 36 years after her last RAI treatment. This case
series demonstrates that some patients with distant metastases, even if metabolically active
and radioactive iodine resistant, remain stable for decades without further treatment.
Clinical awareness of such patients and continual reassessment of disease risk following
initial therapy are crucial as aggressive treatment may not be necessary.
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Introduction
Well-differentiated thyroid cancer is common, easily
identiﬁed, and often curable. While the incidence of
thyroid cancer has nearly tripled in the past three decades,
mortality rates have remained stable ( 1 ,2 ,3 ) .T h i s
underscores the widespread success in identifying,
treating, and thereby limiting disease-related harm in
most affected individuals (4, 5). Yet paradoxically, such
features may have simultaneously hindered our ability to
prospectively investigate the natural history of this illness
and deﬁne the optimal extent of necessary treatment.
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nearly seven decades, the recommended treatment for
biopsy-proven disease has been surgical thyroidectomy,
and radioactive iodine (RAI) (
131I) ablation, followed by
thyroid hormone suppression therapy (6, 7, 8, 9). Though
there may be beneﬁts to this approach, especially for
patients with advanced disease, increasing evidence
conﬁrms that such a standardized approach to care may
not be equally effective for all patients (10, 11, 12).
For example, attention has recently been focused
upon the necessity for (and the optimal dosing of)
131Ii n
the treatment of papillary thyroid carcinoma. Two
separate prospective trials conﬁrmed the equivalency of
30 and 100 mCi
131I dosing for post-surgical remnant
ablation (13, 14). At a follow-up of two years, both studies
demonstrated effective remnant ablation in 85–90% of
patients, depicting lower side-effect proﬁles, costs, and
complication rates when 30 mCi
131I was administered.
These ﬁndings have led to frequent adoption of 30 mCi
131I for the treatment of low-risk patients (15, 16).I n
addition, a recent study has also shown an equivalent
efﬁcacy by low-dose RAI on tumor outcome in patients
with intermediate tumor risk (17). More broadly, such
prospective and randomized data have also raised ques-
tions about the necessity, extent, and duration of
treatment for all thyroid cancer patients, even those
with advanced or metastatic disease. Importantly, there
currently exist no randomized controlled trials comparing
131I with placebo. As a consequence of these studies, there
has been a paradigm shift over the past two decades to
individualize risk assessment and treatment strategies in
an effort to avoid potential harm, especially in patients
with low-risk disease (10, 11, 12, 18, 19, 20).
However, these concepts are more difﬁcult to apply
in patients with advanced disease, given their guarded
prognosis. The 10-year survival rate for patients with
distant metastatic thyroid cancer ranges from 26 to 60%
(21, 22, 23). As a result, more aggressive and repeated
therapies are often employed. For instance, most patients
with pulmonary metastases are considered for repeated
RAI treatment so long as iodine avidity is still conﬁrmed.
This approach, while seemingly logical, nonetheless
remains untested when compared with a more conserva-
tive regimen.
Observations have suggested that a subset of such
patients may challenge the conventional dogma regarding
the progressive nature of all thyroid malignancies with
distant metastases. Some patients, who have widely
metastatic and seemingly persistent thyroid cancer,
demonstrate minimal progression of their disease over
years despite no further treatment beyond TSH
suppression. Clinician awareness of this unique group is
crucial as conventional treatment protocols may not be
fully applicable. In this paper, we present a case series of
patients with distant metastatic thyroid cancer whose
disease remained quiescent without observable pro-
gression of pulmonary metastases for decades. While
standard initial therapy was administered, such therapy
did not eliminate all malignant tissues as proven by
biopsies of metastatic foci and evidence of metabolic
activity on PET and radionuclide scans. These data suggest
that persistent distant metastatic thyroid cancer in some
patients can be effectively managed over time with only
TSH-suppressive therapy.
Methods
We searched in the thyroid nodule database of
the Brigham and Women’s Hospital (BWH) to identify
patients with long-standing yet stable thyroid cancer
metastases. To expand our search, we also surveyed
thyroidologists at BWH and at afﬁliated institutions.
Criteria used for identiﬁcation included the following.
All patients were initially diagnosed with well-differen-
tiated thyroid cancer (papillary or follicular carcinoma),
conﬁrmed histopathologically following thyroidectomy.
Distant metastatic disease was ﬁrst identiﬁed by imaging
at the time of initial staging or during follow-up
surveillance. All patients have pulmonary metastatic
disease and some have additional regional nodal disease.
Importantly, metastatic foci were conﬁrmed by tissue
biopsy in all cases. Of the 6665 patients consecutively
enrolled in the BWH thyroid nodule database, 791
patients proved to have papillary thyroid carcinoma
(PTC). Of these, w25–35 patients have been found to
have conﬁrmed or suspected distant metastatic disease.
Several post-
131I nuclear scans have shown possible,
though not conclusive, iodine uptake at distant metastatic
sites. As we cannot deﬁnitively conﬁrm metastatic disease
without tissue sampling (which many did not receive), we
acknowledge a level of uncertainty to this calculation.
All patients received standard therapy for their illness,
including thyroidectomy followed by
131I administration.
All patients were prepared for
131I therapy using thyroid
hormone withdrawal. Typically, doses of w75–200 mCi
131I were administered, and post-therapy whole-body
scanning was performed 3–9 days thereafter. Patient
follow-up and repeat assessments were performed as per
the practice of the treating endocrinologist. In general,
patients were monitored by biochemical testing including
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cross-sectional imaging. Monitoring generally occurred
biannually or annually.
Ideally, the goal of
131I therapy was to destroy thyroid
follicular cells, including those that were malignant.
When this happens, metastatic foci or adenopathy can
remain anatomically abnormal due to ﬁbrosis or scarring.
In such cases, while malignant cells are not present,
imaging may detect persistent abnormality. Our goal was
to exclude such cases, as they represent effectively treated
disease. Thus, we included only subjects for whom we
could identify persistent and/or metabolically active
metastatic disease despite initial treatment. For this
study, persistent disease was conﬁrmed histologically
with lung biopsy at a time distant from initial therapy.
Lesions were also noted on cross-sectional imaging
and increasing thyroglobulin concentration (or new
anti-thyroglobulin antibodies) was commonly detected
after decades. Metabolically active metastatic disease was
deﬁned as positive FDG uptake on PET scanning or
lung radioactive iodine uptake upon radionuclide scan-
ning consistent with metastatic disease. Permission was
obtained from the BWH Institutional Review Board to
perform this analysis.
Results
A case series of ﬁve patients is described below and in
Table 1.
Patient no. 1
A 45-year-old woman was referred for evaluation of
persistent metastatic papillary thyroid carcinoma. The
patient was ﬁrst diagnosed with papillary carcinoma and
diffuse pulmonary metastases in 1975 at age eight. Owing
to the risks associated with therapy, observation was
initially favored. Three years later (age 10 years), chest
X-ray demonstrated progression of pulmonary metastatic
disease. Near-total thyroidectomy and left neck dissection
were performed. Histology reported it as a papillary
carcinoma with extensive extrathyroidal involvement
invading into the trachea and with extensive cervical
lymph node metastases. Shortly thereafter, 80 mCi of
131I
was administered, followed by a second dose of 150 mCi
5 months later. Post-therapy scans conﬁrmed diffuse
pulmonary and left neck uptake consistent with distant
metastatic carcinoma. Suppressive doses of levothyroxine
were administered.
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received no further therapy and remained in good health,
but demonstrated persistently elevated thyroglobulin
levels (range 25–57 ng/ml) on intermittent follow-up.
At the age of 45, the patient re-established medical care.
Evaluation revealed a serum thyroglobulin level of
25 ng/ml. Chest computed tomography (CT) demon-
strated innumerable bilateral pulmonary nodules ranging
from 5 to 10 mm. Whole-body scanning performed with
123I revealed faint uptake in the left neck as well as 1.5%
uptake in each lung ﬁeld (3% total lung uptake). PET scan
conﬁrmed some lung foci to be FDG avid. Ultrasound
of the neck was negative for signs of local recurrence.
CT-guided core needle biopsy of the pulmonary nodules
conﬁrmed persistent metastatic papillary thyroid carci-
noma. The patient has been monitored for 2 years, with
follow-up testing demonstrating variable thyroglobulin
levels (25–40 ng/ml), though without upward trend. Her
most recent thyroglobulin concentration was 33 ng/ml.
Repeated chest CT revealed no change in nodularity. Aside
from chronic, moderate shortness of breath attributed to
vocal cord dysfunction, the patient remains asymptomatic
despite her persistent, stable, iodine avid pulmonary
metastases that have remained untreated for 36 years.
Patient no. 2
A 28-year-old female presented with a thyroid mass.
Evaluation led to total thyroidectomy and neck dissection.
Multifocal papillary thyroid carcinoma, up to 3 cm in size,
with capsular invasion was diagnosed. Fifteen cervical
lymph nodes were positive for local metastatic disease.
The patient received 150 mCi of
131I revealing extensive
(5%) neck uptake highly suspicious for residual nodal
disease. No uptake was noted in the lung ﬁelds or bony
structures. During follow-up, thyroglobulin was persist-
ently detectable with concentrations of w19 ng/ml. A CT
scan revealed bilateral pulmonary nodules ranging from
2 to 5 mm in diameter. No further treatment was provided
at thattime. One year later (age 29), thepatient underwent
a second right neck dissection due to persistent disease.
A second 150 mCi dose of
131I was administered, with no
post-treatment evidence of lung uptake. Two additional
neck surgeries were performed at ages 33 and 35 for
persistent malignant lymphadenopathy. Since age 29, no
further
131I or systemic treatment was administered
beyond TSH suppression.
The patient remained stable for 11 years with
unchanged pulmonary nodules on repeat cross-sectional
imaging. Stimulated thyroglobulin ranged from 1.9 to
2.5 ng/ml over the ﬁrst 6 years, though was once reported
as undetectable. However, she later developed anti-
thyroglobulin antibodies, which have since persisted.
At the age of 40, PET scanning revealed multiple
pulmonary nodules that remained unchanged in compari-
son to CT scans 13 years prior, though one 0.6 mm left
lower nodule was FDG-avid. The patient was referred for a
diagnostic video-assisted thoracoscopic surgery (VATS)
wedge resection of the left pulmonary nodule because of
concerns for a possible new malignancy. Histopathology
conﬁrmed persistent, metastatic papillary thyroid carci-
noma. Currently, at the age of 41, the patient is
asymptomatic and fully functional. Her biopsy-proven
pulmonary metastases have remained stable for 12 years.
Patient no. 3
A41-year-oldfemalesoughtmedicalattentionforathyroid
mass. Neck ultrasound revealed a 3.8 cm left thyroid
nodule and FNA proved cytologically suspicious. A near-
total thyroidectomy and left neck dissection were per-
formed. Pathology revealed a 4 cm papillary thyroid
carcinoma with extensive invasion into skeletal muscle
and subcutaneous soft tissues. The surgical resection
margin involved carcinoma and ten cervical lymph nodes
were positive for metastases. She received 142 mCi of
131I
with post-treatment scans revealing only neck (remnant)
uptake. Anti-thyroglobulin antibodies were detected after
therapy with increasing concentrations 4 years later (age
45), leading to chest CT evaluation. CT imaging demon-
strated innumerable bilateral pulmonary nodules, ranging
from 1 to 4 mm in diameter. The patientwas treatedwith a
second 151 mCi dose of
131I, though post-therapy scans
demonstrated no pulmonary or neck uptake. The patient
underwent diagnostic VATS exploration and wedge biopsy
1 month later (4 years after her initial therapy), because of
concerns for a possible new malignancy. Lung histology
was consistent with metastatic papillary thyroid carci-
noma. No further treatment beyond TSH suppression was
provided. The patient has since been followed for 8 years
without further treatment. TSH was maintained sup-
pressed. Despite increasing anti-thyroglobulin antibody
concentrations up to a level of 1000 IU/ml, her repeatneck
ultrasounds and CT scans of the lungs have shown stable
pulmonary metastatic disease for 8 years.
Patient no. 4
A 29-year-old female was observed to have a thyroid
mass in 1968. At that time, she underwent near-total
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Three years after initial diagnosis, she underwent right
neck radical dissection for metastatic lymphadenopathy.
At the age of 33, a chest X-ray showed bilateral pulmonary
nodules. A decision was made to treat her with 75 mCi of
131I. Post-therapy radionuclide scanning demonstrated no
pulmonary uptake. Given the concern for another malig-
nancy, the patient was referred for diagnostic wedge
resection of the two right lung nodules. Histopathology
conﬁrmed metastatic papillary thyroid carcinoma. After
her radioactive iodine therapy at the age of 33, the patient
has received no further treatment beyond thyroid hor-
mone-suppressive therapy. Since age 53, the patient has
undergone annual CT scans of the lungs revealing
persistent, but stable, pulmonary metastases measuring
2–4 mm in diameter without new nodules or progressive
enlargement of the existing nodules. Repeat neck sono-
graphy has revealed no evidence of local recurrent disease.
Anti-thyroglobulin antibodies developed at the age of
59, and concentrations have remained positive, though
variable. Despite biopsy-proven pulmonary metastasis,
the patient has been asymptomatic and healthy. At the
age of 75, patient had stable pulmonary metastases for
42 years.
Patient no. 5
In 1966, a 43-year-old female underwent hemi-thyroid-
ectomy revealing papillary thyroid carcinoma. No other
therapy was recommended at that time. After 12 years, she
developed recurrent disease and underwent complete
thyroidectomy. She did not receive further treatment
except for thyroid hormone suppression and experienced
an unremarkable course for the next 34 years until a
mediastinal mass was detected at the age of 77 years.
Ac h e s tC Tc o n ﬁ r m e da2 . 5 c mm e d i a s t i n a lm a s sa s
well as numerous micro- and macro-pulmonary nodules
measuring 3–12 mm in diameter. A PET scan showed
intense FDG avidity in the sternal mass and mild avidity
in a left lung nodule. She underwent resection of the
mediastinal mass, conﬁrming PTC with tall cell features.
The patient was treated with radioactive iodine therapy
(203 mCi dose) but demonstrated no pulmonary uptake.
Given concerns for possible pulmonary sarcoidosis and
a separate malignancy, diagnostic thoracoscopic wedge
resection of the left lower lung was performed 2 months
later. This conﬁrmed metastatic papillary carcinoma. No
further treatment was provided. For the next 8 years, the
patient was monitored with CT scans of the chest
demonstrating persistent, but stable, pulmonary
metastases. Follow-up testing demonstrated variable thyr-
oglobulin levels (2.2–4.8 ng/ml), though without upward
trend. She did have recurrent neck metastases that were
resected at ages 81 and 85 years respectively. Pathology
conﬁrmed metastatic papillary carcinoma. From age 85
to 87, CT scans showed mild enlargement of pulmonary
metastasis but stabilization thereafter. At the age of 89, the
patient was unfortunately diagnosed with breast carci-
noma and biopsy-proven breast cancer metastasis to the
liver and bone. She died within 12 months from rapidly
progressing breast cancer. At the time of death, the patient
had thyroid cancer for over 47 years, withpersistent, stable
pulmonary metastases disease for 13 years.
Discussion
Theincidenceofthyroidcancerhasbeenincreasing(1,3,24).
Most patients demonstrate low-risk, localized disease,
which confers an outstanding long-term survival
following treatment (4, 5). However, a minorityof patients
present with distant metastatic disease, often viewed as
life threatening. While the majority of deaths from
thyroid carcinoma (2) are indeed those with distant
metastatic disease (23, 25, 26), our data demonstrate a
remarkable diversity in the natural progression of patients
with advanced thyroid cancer. We identiﬁed ﬁve individ-
uals initially diagnosed with well-differentiated thyroid
carcinoma (WDTC), who underwent surgery and
131I
therapy. However, concerns for separate malignancies
led to biopsy of metastatic foci at time-points far distant
from the initial diagnosis (mean: 19 years). In each case,
histopathological analysis conﬁrmed persistent, generally
stable pulmonary metastases long after the completion of
initial therapy. Persistent disease was further supported by
elevated serum thyroglobulin levels in two patients and
the development of new (or rising) anti-thyroglobulin
antibodies in the other three patients. Abnormal uptake
on PET scanning (nZ3) and/or persistent iodine uptake on
radionuclide scanning (nZ1) conﬁrmed metabolic
activity in these persistent, yet stable, foci of cancer. The
lack of disease progression was assessed by a careful review
of repeat imaging and the subsequent clinical follow-up,
while no further therapy was administered beyond thyroid
hormone suppression. Together, these data conﬁrm the
remarkable ability of select distant metastatic WDTC to
persist yet remain stable for decades (mean 22 years, range
8–42 years) despite evidence of metabolic activity.
Our data do not provide metrics allowing us to
determine the prevalence of such patients. We estimate
that w4% of the patients diagnosed with PTC at BWH
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notable for the inclusion criteria, which mandated lung
biopsy and histological conﬁrmation of persistent meta-
static cancer at a later time point. While this protocol was
necessary to prove that persistent lung nodules were not
simply effectively treated (and destroyed) WDTC tissue,
these criteria almost certainly underestimate the number
of similar cases that may exist. Although studies have
reported high mortality rates in patients with metastatic
thyroid cancer, those who survived probably shared a fate
similar to our population. In support of this, others have
estimated that up to w30% of patients with metastatic
thyroid cancer remain stable during 10 years of follow-up
(27). In addition, many patients with thyroid cancer and
lung nodules do not undergo invasive lung biopsy or
wedge resection. Most of them are simply monitored
by serial clinical examinations and chest imaging. We
speculate that at our institution, such cases number at
least one per year. Extrapolation to a national level allows
one to postulate that hundreds of patients may prove to
have persistent, yet non-progressive distant metastatic
disease.
Though impossible to identify the predictive charac-
teristics from such a small patient population, it is worth
pointing out some striking ﬁndings. One notable ﬁnding
was the paucity of iodine uptake on post-therapy scans
in the metastases of four patients (patients nos 2–5).
Typically, non-iodine-avid distant metastases are associ-
ated with worse prognoses. However, those in our series
demonstrated stable disease (28, 29). Separately, FDG
positivity on PET scan is also known to be associated with
unfavorable prognoses (30). However, all three patients
with FDG-avid pulmonary metastasis experienced pro-
longed stability. We also note that the patients described
in this series are all women and were relatively young at
the time of diagnosis (mean 29 years). It is well recognized
that younger patients respond better to initial therapy and
experience a longer life expectancy compared with older
patients with a similar disease (6, 31, 32, 33). This case
series also lends support to long-term TSH-suppressive
therapy in patients with distant metastatic thyroid cancer,
as all patients were treated solely by this modality for
decades. However, we acknowledge that no prospective,
randomized study has yet proven the long-term survival
beneﬁt of TSH suppression (34, 35, 36).
Very few published reports exist on this topic.
Vassilopoulou-Sellin et al. (37) reported distant metastatic
papillary carcinoma in a 9-year-old female. She was treated
with surgery, external radiation therapy, and
131I ablation.
Long-term follow-up was unremarkable, though a new
provider detected a lung nodule at the age of 40. Biopsy
demonstrated thyroid carcinoma ultimately proven to be
metabolically active and iodine avid. This is remarkably
similar to patient no. 1 described above. However, few
other comparable reports (18) exist despite epidemiologi-
cal data conﬁrming young patients (!45 years) with
distant metastatic disease may experience a 63–85%
10-year survival rate after initial therapy (33, 38, 39).W e
are conﬁdent that there are many patients who may
experience a similar disease course.
These data have important implications for the
clinical care of patients with WDTC. Importantly, distant
metastatic disease occurs in 2–7% of cases (22, 40, 41, 42)
and should be treated aggressively. It is notable that all
patients in our series underwent initial therapy including
thyroidectomy and neck dissection, followed by
131I
ablation. Some subjects (patients nos 2 and 5) have
substantial or recurrent neck disease that was aggressively
treated and required multiple surgeries. Complete resec-
tion of the local disease (including adenopathy) appears to
be important (15, 30, 31, 34, 43, 44). When resection is not
complete following initial surgery, repeated local dissec-
tions may prove beneﬁcial (15, 45). It is likely that such
therapy was important to their outcome and should be
recommended for similar patients. However, the utility of
repeated
131I dosing, and possible use of systemic
chemotherapy should be questioned, with perhaps more
judicious decision-making favored based upon continued
individual risk assessment and response to treatment, as
advocated by the American Thyroid Association (15).I n
support of this, repeat RAI dosing in the absence of iodine
avidity in metastatic disease has been associated with a
low efﬁcacy on tumor outcome (46). Furthermore, some
patients in our study may have qualiﬁed for enrollment
in clinical trials investigating the use of tyrosine kinase
inhibitors, especially if disease appeared to have anatomi-
cally progressed (patient no. 5). However, a decision for
TKI for treating advanced or even advancing DTC must be
based on continuous assessment of treatment beneﬁt vs
possible toxicity. All patients who have completed initial
surgery and ablation should be monitored by serial
examinations and imaging. Those who remain asympto-
matic and show no signs of anatomic progression may be
candidates for expectant monitoring. We recognize that
some patients will progress. Therefore, we do not advocate
that a singular approach be utilized in all patients, but
rather individualized therapy be provided to optimize
treatment beneﬁt and minimize morbidity.
In conclusion, although the diagnosis of advanced
thyroid cancer usually confers a worse prognosis, this case
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patients with metabolically active distant pulmonary
metastases to persist and remain stable for decades
without further treatment apart from TSH suppression.
Though our data are not sufﬁciently robust to ascertain the
prevalence or predictive characteristics of this cohort, this
study may serve to promote physician awareness of such
a unique subset of patients and highlight the treatment
dilemmas that often arise while managing such patients.
We hope that this case series may serve as a platform upon
which further studies can build to better understand this
complex disease.
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